Phathom Pharmaceuticals announces initiation of pivotal phase 3 clinical trial for vonoprazan in erosive esophagitis

Image: The first phase of the trial will evaluate the efficacy and safety of vonoprazan 20mg administered once-daily compared to lansoprazole 30mg once-daily for the healing of EE for up to eight weeks. Photo: courtesy of moritz320 from Pixabay.